Previous close | 0.4000 |
Open | 0.3000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 52.50 |
Expiry date | 2024-06-21 |
Day's range | 0.3000 - 0.4000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Q1 2024 Kymera Therapeutics Inc Earnings Call
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a p